TWiV 1182: Clinical update with Dr. Daniel Griffin

January 11, 2025

In his weekly clinical update, Dr. Griffin discusses how vaccination and vaccine hesitancy affects public health and disease spread in terms of mpox, the first human death from H5N1 in US, why one should not feed their pets raw pet food and the metapneumonia outbreak in China before reviewing the recent statistics on RSV, influenza and SARS-CoV-2 infections, the WasterwaterScan dashboard, where to find PEMGARDA, how nirmatrelvir-ritonavir/Paxlovid reduces adverse outcomes of COVID in patients with kidney disease, provides information for Columbia University Irving Medical Center’s long COVID treatment center, SARS-CoV-2 infection affects skin conditions including shingles and if long antiviral treatment affects long COVID.

Click arrow to play
Download TWiV 1182 (19 MB .mp3, 31 min)
Subscribe (free): Apple Podcasts, RSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

The post TWiV 1182: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.

Leave a Reply

Your email address will not be published. Required fields are marked *

0 comments on “TWiV 1182: Clinical update with Dr. Daniel Griffin

  1. I enjoyed the discussion of Cpf1 etc.—ask and ye shall receive!

    Another big name in the CRISPR credit discussion is George Church, whose group published on editing back-to-back in Science with Zhang’s group. Fortunately Church does not mind being a bit farther from the limelight: “The whole patent battle is silly. There has been much research. And if anybody should be making a fuss about this I should be making a fuss. But I am not doing that, because I don’t think it matters.”
    Quoted in a nice piece by Specter: http://www.newyorker.com/magazine/2015/11/16/the-gene-hackers

    Church’s lab has also done cool stuff on respecifying codons genome-wide for phage resistance, and possibly other uses.

    Another fun quote, from Doudna, regarding Jill Banfield convincing her to work on CRISPR: “I remember thinking this is probably the most obscure thing I ever worked on.” Further underscores the importance of curiousity-driven fundamental research.
    http://www.nytimes.com/2015/05/12/science/jennifer-doudna-crispr-cas9-genetic-engineering.html

    One of the many new uses of the CRISPR-Cas9 system is to target DNA viruses for disease resistance in plants. Open access perspective on three recent papers: http://www.genomebiology.com/content/16/1/254